Mirum Pharmaceuticals Inc (NASDAQ: MIRM) is 42.21% higher on its value in year-to-date trading and has touched a low of $23.14 and a high of $45.23 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The MIRM stock was last observed hovering at around $43.87 in the last trading session, with the day’s loss setting it -1.89%.
Currently trading at $41.98, the stock is 2.03% and 9.02% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.61 million and changing -4.31% at the moment leaves the stock 38.40% off its SMA200. MIRM registered 61.34% gain for a year compared to 6-month gain of 46.22%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 3.53% loss in the last 1 month and extending the period to 3 months gives it a 71.77%, and is 2.44% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.06% over the week and 4.95% over the month.
Mirum Pharmaceuticals Inc (MIRM) has around 264 employees, a market worth around $2.00B and $264.38M in sales. Profit margin for the company is -40.34%. Distance from 52-week low is 81.42% and -7.19% from its 52-week high. The company has generated returns on investments over the last 12 months (-19.59%).
Mirum Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -0.43 with sales reaching $81.56M over the same period.The EPS is expected to grow by 55.09% this year, but quarterly earnings will post 69.10% year-over-year. Quarterly sales are estimated to grow 70.90% in year-over-year returns.
240.0 institutions hold shares in Mirum Pharmaceuticals Inc (MIRM), with institutional investors hold 120.47% of the company’s shares. The shares outstanding are 46.72M, and float is at 37.84M with Short Float at 18.16%. Institutions hold 117.73% of the Float.
The top institutional shareholder in the company is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with over 6.5 million shares valued at $222.08 million. The investor’s holdings represent 13.8413 of the MIRM Shares outstanding. As of 2024-06-30, the second largest holder is JANUS HENDERSON GROUP PLC with 4.99 million shares valued at $170.56 million to account for 10.6307 of the shares outstanding. The other top investors are BVF INC/IL which holds 4.37 million shares representing 9.3123 and valued at over $149.41 million, while EVENTIDE ASSET MANAGEMENT, LLC holds 7.703 of the shares totaling 3.61 million with a market value of $123.59 million.
Mirum Pharmaceuticals Inc (MIRM) Insider Activity
The most recent transaction is an insider sale by Howe Jolanda, the company’s SVP, GLOBAL CONTROLLER. SEC filings show that Howe Jolanda sold 375 shares of the company’s common stock on Jul 02 ’24 at a price of $34.00 per share for a total of $12750.0. Following the sale, the insider now owns 2426.0 shares.
Mirum Pharmaceuticals Inc disclosed in a document filed with the SEC on Jun 24 ’24 that Vig Pamela (CHIEF SCIENTIFIC OFFICER) sold a total of 30,559 shares of the company’s common stock. The trade occurred on Jun 24 ’24 and was made at $34.00 per share for $1.04 million. Following the transaction, the insider now directly holds 27406.0 shares of the MIRM stock.
Still, SEC filings show that on Jun 05 ’24, Ramasastry Saira (Director) disposed off 5,000 shares at an average price of $25.68 for $0.13 million. The insider now directly holds 0 shares of Mirum Pharmaceuticals Inc (MIRM).
